Company Filing History:
Years Active: 2021
Title: Ji Yeon Lim: Innovator in Self-Immolative Linkers
Introduction
Ji Yeon Lim is a prominent inventor based in Daejeon, South Korea. She has made significant contributions to the field of biochemistry, particularly in the development of innovative compounds that enhance the delivery of active agents within target cells. Her work is characterized by a focus on self-immolative linkers that can be utilized in various applications, including drug delivery and targeted therapies.
Latest Patents
One of Ji Yeon Lim's notable patents is titled "Compound bearing beta-galactoside-introduced self-immolative linker." This invention relates to a compound that features a self-immolative linker with a β-galactoside moiety. The self-immolative linker is designed to form glycosidic bonds with proteins or ligands that have a specific affinity for desired targets. This innovative approach allows for the selective release of active agents, such as drugs or detection probes, within target cells, thereby enhancing therapeutic efficacy.
Career Highlights
Ji Yeon Lim is currently associated with Intocell, Inc., where she continues to advance her research in the field of biochemistry. Her work has garnered attention for its potential applications in medical and pharmaceutical industries. With her expertise, she is paving the way for new methodologies in targeted drug delivery systems.
Collaborations
Throughout her career, Ji Yeon Lim has collaborated with esteemed colleagues, including Tae Kyo Park and Sung Ho Woo. These collaborations have further enriched her research and contributed to the development of innovative solutions in her field.
Conclusion
Ji Yeon Lim is a trailblazer in the realm of self-immolative linkers, with her patent showcasing the potential for targeted drug delivery. Her contributions to biochemistry are paving the way for advancements in therapeutic applications.